



ASO VISUAL ABSTRACT


ASO Visual Abstract: Treatment and Survival Outcomes of Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study

Michelle V. Dietz, MD¹, Merijn J. Ziekman, MD¹, Job P. van Kooten, MD¹, Alexandra R. M. Brandt-Kerkhof, MD¹, Esther van Meerten, MD, PhD², Cornelis Verhoef, MD, PhD¹, and Eva V. E. Madsen, MD, PhD¹

¹Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; ²Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Patients with colorectal peritoneal metastases were most commonly deemed ineligible for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy because of extensive peritoneal metastases. These patients had

worse survival outcomes than patients deemed ineligible because of extra-peritoneal metastases (<https://doi.org/10.1245/s10434-022-12969-0>).



Michelle V. Dietz and Merijn J. Ziekman have contributed equally to this work.

DISCLOSURES There are no conflicts of interests.

© Society of Surgical Oncology 2023

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published Online: 31 January 2023

M. V. Dietz, MD
e-mail: m.dietz@erasmusmc.nl